Stay updated with breaking news from Stephenj Schuster. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.
Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.
The FDA has approved Kymriah (tisagenlecleucel) for adults with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma